Literature DB >> 21631691

Optimizing vaccine development.

Daniel F Hoft1, Vladimir Brusic, Isaac G Sakala.   

Abstract

Optimizing the development of modern molecular vaccines requires a complex series of interdisciplinary efforts involving basic scientists, immunologists, molecular biologists, clinical vaccinologists, bioinformaticians and epidemiologists. This review summarizes some of the major issues that must be carefully considered. The intent of the authors is to briefly describe key components of the development process to give the reader an overview of the challenges faced from vaccine concept to vaccine delivery. Every vaccine requires unique features based on the biology of the pathogen, the nature of the disease and the target population for vaccination. This review presents general concepts relevant for the design and development of ideal vaccines protective against diverse pathogens.
© 2011 Blackwell Publishing Ltd.

Mesh:

Substances:

Year:  2011        PMID: 21631691     DOI: 10.1111/j.1462-5822.2011.01609.x

Source DB:  PubMed          Journal:  Cell Microbiol        ISSN: 1462-5814            Impact factor:   3.715


  13 in total

1.  Vaccine strategies against cystic fibrosis pathogens.

Authors:  Vincent Le Moigne; Jean-Louis Gaillard; Jean-Louis Herrmann
Journal:  Hum Vaccin Immunother       Date:  2016-03-03       Impact factor: 3.452

Review 2.  InCVAX--a novel strategy for treatment of late-stage, metastatic cancers through photoimmunotherapy induced tumor-specific immunity.

Authors:  Feifan Zhou; Xiaosong Li; Mark F Naylor; Tomas Hode; Robert E Nordquist; Luciano Alleruzzo; Joseph Raker; Samuel S K Lam; Nan Du; Lei Shi; Xiuli Wang; Wei R Chen
Journal:  Cancer Lett       Date:  2015-01-26       Impact factor: 8.679

3.  MgtC as a Host-Induced Factor and Vaccine Candidate against Mycobacterium abscessus Infection.

Authors:  Vincent Le Moigne; Claudine Belon; Céline Goulard; Geoffrey Accard; Audrey Bernut; Bruno Pitard; Jean-Louis Gaillard; Laurent Kremer; Jean-Louis Herrmann; Anne-Béatrice Blanc-Potard
Journal:  Infect Immun       Date:  2016-09-19       Impact factor: 3.441

4.  Comparisons of the Humoral and Cellular Immune Responses Induced by Live Attenuated Influenza Vaccine and Inactivated Influenza Vaccine in Adults.

Authors:  Daniel F Hoft; Kathleen R Lottenbach; Azra Blazevic; Aldin Turan; Tamara P Blevins; Thomas P Pacatte; Yinyi Yu; Michelle C Mitchell; Stella G Hoft; Robert B Belshe
Journal:  Clin Vaccine Immunol       Date:  2017-01-05

Review 5.  The use of plants for the production of therapeutic human peptides.

Authors:  Chiara Lico; Luca Santi; Richard M Twyman; Mario Pezzotti; Linda Avesani
Journal:  Plant Cell Rep       Date:  2012-01-05       Impact factor: 4.964

Review 6.  Mucosal vaccines and technology.

Authors:  A Miquel-Clopés; E G Bentley; J P Stewart; S R Carding
Journal:  Clin Exp Immunol       Date:  2019-04-08       Impact factor: 4.330

Review 7.  Chitin, chitosan, and glycated chitosan regulate immune responses: the novel adjuvants for cancer vaccine.

Authors:  Xiaosong Li; Min Min; Nan Du; Ying Gu; Tomas Hode; Mark Naylor; Dianjun Chen; Robert E Nordquist; Wei R Chen
Journal:  Clin Dev Immunol       Date:  2013-03-04

8.  Immunogenic and invasive properties of Brucella melitensis 16M outer membrane protein vaccine candidates identified via a reverse vaccinology approach.

Authors:  Gabriel Gomez; Jianwu Pei; Waithaka Mwangi; L Garry Adams; Allison Rice-Ficht; Thomas A Ficht
Journal:  PLoS One       Date:  2013-03-22       Impact factor: 3.240

9.  Mucosal Immune System and M Cell-targeting Strategies for Oral Mucosal Vaccination.

Authors:  Sae-Hae Kim; Kyung-Yeol Lee; Yong-Suk Jang
Journal:  Immune Netw       Date:  2012-10-31       Impact factor: 6.303

Review 10.  Antigen targeting to M cells for enhancing the efficacy of mucosal vaccines.

Authors:  Sae-Hae Kim; Yong-Suk Jang
Journal:  Exp Mol Med       Date:  2014-03-14       Impact factor: 8.718

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.